Vijay has a multidisciplinary background with a particular interest in drug discovery and development. After studying Veterinary Medicine in India, Vijay earned an MSc in Neuro-Molecular Pharmacology at the University of Bristol and then a PhD in Physiology at the same University in 2002. During the past 16 years, Vijay has been a senior lecturer at a reputed Healthcare University College in the UK.
Harsha, with multidisciplinary know-how, brings vast knowledge in target discovery and signalling mechanisms, two of the most exciting aspects of drug development. Harsha studied Pharmacy in India and earned an MSc in Pharmacology and Biotechnology from Sheffield Hallam University in the UK. He completed his PhD in Molecular and Cellular Neuroscience in 2005 at the MRC Centre for Synaptic Plasticity, the University of Bristol, UK. For almost six years, Harsha worked at the same institution in Bristol and elucidated the neuronal receptors signalling mechanisms, trafficking, and functional roles. Currently, Harsha is an academic staff member at a reputed University in the UK.
Srikumar Nimmala is an ambitious software tech expert from the USA. After completing his MSc in Endocrinology and Genetics from Osmania University, he did Batchlor of Laws from Osmania university in Hyderabad, India, Srikumar indulged in a long journey of practical experience and professional learning in Information Technology to date. Srikumar has productively served as a software application architect at several big pharmaceutical and fortune 500 comapnies in his career and brings a vast and diverse experience of almost 23 years.
Professor Robert Falconer
Head of Translational Development
Professor Falconer, Director of the Institute of Cancer Therapeutics, is a medicinal chemist and registered pharmacist with over 25 years of expertise in oncology drug discovery. Holding a PhD from UCL, his research focuses on protease-activated prodrugs and antimetastatic agents. A Professor since 2019, he leads a productive team and oversees a £2M Doctoral Training Centre. He has secured significant funding from UKRI and Wellcome Trust, holds patents for commercialized therapies, and co-founded Incanthera plc. A Fellow of the Royal Society of Chemistry, he works closely with industry partners to develop innovative nanoparticle-based cancer therapeutics with real-world clinical impact.
Professor Klaus Pors
Head of Targeted Therapeutics and Innovation
Professor Pors is a leading chemical biologist at the University of Bradford’s School of Pharmacy & Medical Sciences. With a PhD from UCL, his research bridges chemistry and biology to develop tumour-selective therapies. He focuses on hypoxia-activated prodrugs, resistance mechanisms, and tumour microenvironments. His lab developed Alchemix and duocarmycin bioprecursors—both commercialized by biotech firms—and co-founded Incanthera Ltd. He also pioneered CyTRAK™ and DRAQ9™, far-red viability probes used in live-cell assays. Joining ICT in 2005, he became a professor in 2021 and continues to drive innovation in anticancer therapeutics with translational impact across academia and industry.
Richard Boyd brings exceptional depth as a biotech and medtech leader, having founded, led or advised multiple successful university spinouts, including Invizius and VueKlar Cardiovascular. With a track record of raising almost £14 million in equity and grants, he has navigated complex clinical and regulatory landscapes, from IP development to first-in-human trials. His engineering and MBA background, combined with decades of experience in venture development and strategic consultancy, make him an invaluable advisor. Richard's insight into commercialisation, investor engagement, and market strategy directly strengthens Hado Therapeutics' growth, funding readiness, and translational pathway in oncology.
Dr. Raman Narukulla, a highly experienced medicinal chemist with over two decades of drug discovery expertise, holds an MSc in Organic Chemistry and a PhD in Bio-Organic & Medicinal Chemistry. He served as a Senior Research Scientist at Eurofins from June 2019 to January 2023 and at Charles River Laboratories from October 2006 to May 2019. Throughout his career, Raman made pivotal contributions to advance medicinal chemistry. His innovative approach resulted in developing new synthetic routes for therapeutic targets, ensuring the prompt delivery of high-quality compounds for in vitro and in vivo studies. His versatile involvement in therapeutic research projects addressing conditions like COPD, oncology, and rheumatoid arthritis underscores his broad skill set.